In the only randomized comparative study I'm aware of, they're both about
equal on that dimension in the long term.
Grills et al. said...
Biochemical control was 97% and 98% for LDR and HDR, respectively.
HDR brachytherapy alone was associated with decreased acute rates of:
• grade 1 to 3 dysuria (67% versus 36%)
• urinary frequency/urgency (92% versus 54%), and
• rectal pain (20% versus 6%).
Selected chronic toxicities were also decreased with HDR, including long-term:
• urinary frequency and urgency, 32% (HDR) vs 56% (103Pd)
There were no differences in the rates of:
• chronic dysuria
• urinary incontinence
• retention or
• hematuria.
Urethral stricture rates were 8% in the HDR alone group vs 3% for 103 Pd (not statistically different).
The 3-year actuarial impotence rate was 45% for the LDR group and only 16% for HDR.
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.In the
short term, UW Seattle, arguably the best,
reported 43% acute urinary retention in 2002 -- I don't know if they've improved on that or not since then.
Washington U reported a similar rate - 34%. HDR (Demanes] reported 13% Grade 2 & 3 urinary retention (10% & 3% respectively). FYI, Katz using SBRT reported no urinary retention requiring treatment (acute or late, with only 4% Grade 2 urinary SEs).